Romosozumab proves to be effective and safe for treating osteoporosis in men

Primary tabs

NEWS
Romosozumab proves to be effective and safe for treating osteoporosis in men

A reccent study reported the role of romosozumab drug in the traetment of osteoporosis (OS), especially in men. This drug works by inhibiting the protein sclerostin and has a dual effect on bone, both increasing bone formation and decreasing bone resorption.

According to Lewiecki E M, Romosozumab has the ability to improve bone mass, structure and strength by both increasing bone formation and decreasing bone resorption. “These phase III findings are particularly promising as they show the clinical effects of romosozumab in men with osteoporosis – a population that is often under-recognized and under-treated for a disease that can have devastating consequences.

The BRIDGE study (placebo-controlled study evaluatIng the efficacy and safety of romosozumab in treating men with osteoporosis) involved 245 men with OA. Patients received either romosozumab 210 mg subcutaneously (SC) every month (n=163) or placebo SC every month (n=82) for 12 months. All patients also received calcium and vitamin D supplements. A statistically significant increase in bone mineral density (BMD) was reported at month 12 when compared to placebo group in the lumbar spine as assessed by dual-energy X-ray absorptiometry (primary endpoint). The secondary endpoints were also achieved, which included statistically significant BMD increases at month 12 at the femoral neck and total hip, as well as statistically significant BMD increases at month 6 at the lumbar spine, femoral neck and total hip as compared to placebo.

In the romosozumab and placebo groups, adverse events were reported. The most frequently reported adverse events (greater than five percent in the romosozumab arm) were nasopharyngitis, back pain, hypertension, headache and constipation. The findings of this study confirmed that the dual action of romosozumab and ability to improve bone mass, structure and strength by both increasing bone formation and decreasing bone resorption.

Source:

Spinal news international

Link to the source:

https://spinalnewsinternational.com/romosozumab-leads-to-significant-bon...

Original title of article:

Romosozumab leads to significant bone mineral density gains at lumbar spine in osteoporotic men

Authors:

E Michael Lewiecki

Spinal news international
Log in or register to post comments